Perrigo says Revenue has rejected tax offer US drugmaker Perrigo has said that Revenue has rejected an offer to settle a €1.64 billion tax bill it claims the company owes for back taxes. Business • 13 May 21
Perrigo says Revenue has rejected tax offer US drugmaker Perrigo has said that Revenue has rejected an offer to settle a €1.64 billion tax bill it claims the company owes for back taxes. Business • 13 May 21
Perrigo action over disputed €1.64bn tax bill adjourned A judicial review of a decision by Revenue to issue pharmaceutical company Perrigo with a tax bill for €1.64bn will not now formally begin until tomorrow. Business • 03 Jun 20
Perrigo action over disputed €1.64bn tax bill adjourned A judicial review of a decision by Revenue to issue pharmaceutical company Perrigo with a tax bill for €1.64bn will not now formally begin until tomorrow. Business • 03 Jun 20
Perrigo seeks judicial review of €1.6bn tax ruling An Irish registered pharmaceutical company has been granted permission by the High Court to bring a judicial review application aimed at overturning a €1.6 billion tax demand by Revenue. Business • 25 Feb 19
Perrigo seeks judicial review of €1.6bn tax ruling An Irish registered pharmaceutical company has been granted permission by the High Court to bring a judicial review application aimed at overturning a €1.6 billion tax demand by Revenue. Business • 25 Feb 19
Revenue issues €1.6 billion tax demand against Perrigo The Revenue Commissioners have issued pharmaceutical company Perrigo, formerly known as Elan, with a tax demand for €1.6 billion. Business • 21 Dec 18
Revenue issues €1.6 billion tax demand against Perrigo The Revenue Commissioners have issued pharmaceutical company Perrigo, formerly known as Elan, with a tax demand for €1.6 billion. Business • 21 Dec 18
Perrigo completes Elan deal Perrigo has completed the acquisition of Elan in a deal valued at about $8.6 billion. Business • 19 Dec 13
Perrigo completes Elan deal Perrigo has completed the acquisition of Elan in a deal valued at about $8.6 billion. Business • 19 Dec 13
Elan and Perrigo get High Court approval for deal Elan has said the High Court has approved the sale of the company to pharmaceutical firm Perrigo. Business • 13 Dec 13
Elan and Perrigo get High Court approval for deal Elan has said the High Court has approved the sale of the company to pharmaceutical firm Perrigo. Business • 13 Dec 13
Elan shareholders approve Perrigo takeover deal Elan’s shareholders have given approval to the company’s acquisition by pharmaceutical firm Perrigo. Business • 18 Nov 13
Elan shareholders approve Perrigo takeover deal Elan’s shareholders have given approval to the company’s acquisition by pharmaceutical firm Perrigo. Business • 18 Nov 13
Perrigo keen to complete Elan deal by year end US pharmaceutical company Perrigo has said it is working hard to close its acquisition of Elan by the end of the year. Business • 01 Nov 13
Perrigo keen to complete Elan deal by year end US pharmaceutical company Perrigo has said it is working hard to close its acquisition of Elan by the end of the year. Business • 01 Nov 13
Elan reports net loss of $13.8m for Q3 Irish pharmaceutical company Elan has reported a net loss of $13.8 million for the third quarter. Business • 24 Oct 13
Elan reports net loss of $13.8m for Q3 Irish pharmaceutical company Elan has reported a net loss of $13.8 million for the third quarter. Business • 24 Oct 13
US drugmaker Perrigo to buy Elan for $8.6 billion US generic drugmaker Perrigo has agreed to buy Dublin based drug company Elan for $8.6 billion. Business • 29 Jul 13
US drugmaker Perrigo to buy Elan for $8.6 billion US generic drugmaker Perrigo has agreed to buy Dublin based drug company Elan for $8.6 billion. Business • 29 Jul 13
Elan sees net loss for continuing operations in Q2 Elan has said that its revenue from continuing operations for the second three months of its financial year was $56.3 million. Business • 24 Jul 13
Elan sees net loss for continuing operations in Q2 Elan has said that its revenue from continuing operations for the second three months of its financial year was $56.3 million. Business • 24 Jul 13
Elan shareholders approve one of four proposals Elan shareholders have approved a share repurchase programme at an extraordinary general meeting in Dublin. Business • 17 Jun 13
Elan shareholders approve one of four proposals Elan shareholders have approved a share repurchase programme at an extraordinary general meeting in Dublin. Business • 17 Jun 13
Elan begins process of finding a buyer Elan is to begin the process of finding a buyer after the company said it had received a number of expressions of interest. Business • 14 Jun 13
Elan begins process of finding a buyer Elan is to begin the process of finding a buyer after the company said it had received a number of expressions of interest. Business • 14 Jun 13
Royalty granted injunction over change to Elan bid Royalty Pharma has been granted a High Court injunction which could save its hostile bid for Elan even if some votes go against it at a meeting of the Irish drug company's shareholders next week. Business • 13 Jun 13
Royalty granted injunction over change to Elan bid Royalty Pharma has been granted a High Court injunction which could save its hostile bid for Elan even if some votes go against it at a meeting of the Irish drug company's shareholders next week. Business • 13 Jun 13
Elan experience questioned by former board member A former board member of Elan has questioned the experience and competence of the company's management and claims its proposed transactions are "value destructive". Business • 12 Jun 13
Elan experience questioned by former board member A former board member of Elan has questioned the experience and competence of the company's management and claims its proposed transactions are "value destructive". Business • 12 Jun 13
Elan withdraws case against Royalty Pharma bid Elan has withdrawn its US lawsuit against Royalty Pharma over the amount of information provided in relation to its bid for the Irish biotech firm. Business • 11 Jun 13
Elan withdraws case against Royalty Pharma bid Elan has withdrawn its US lawsuit against Royalty Pharma over the amount of information provided in relation to its bid for the Irish biotech firm. Business • 11 Jun 13
Royalty Pharma raises bid for Elan Royalty Pharma today raised its hostile bid for Elan to a potential $8 billion, coming back for the third time after just 7.5% of shareholders accepted the last offer. Business • 07 Jun 13
Royalty Pharma raises bid for Elan Royalty Pharma today raised its hostile bid for Elan to a potential $8 billion, coming back for the third time after just 7.5% of shareholders accepted the last offer. Business • 07 Jun 13
Courts temporarily stop Royalty's bid for Elan Elan has gotten some relief from a US court, which has temporarily restrained investment firm Royalty Pharma from proceeding with its hostile bid for the company. Business • 04 Jun 13
Courts temporarily stop Royalty's bid for Elan Elan has gotten some relief from a US court, which has temporarily restrained investment firm Royalty Pharma from proceeding with its hostile bid for the company. Business • 04 Jun 13
Elan has 'Plan B' if shareholders reject deals Elan said it will lay out an alternative strategy if shareholders reject a string of planned deals. Business • 30 May 13
Elan has 'Plan B' if shareholders reject deals Elan said it will lay out an alternative strategy if shareholders reject a string of planned deals. Business • 30 May 13
Elan's board rejects Royalty Pharma's latest bid Elan’s board has unanimously rejected Royalty Pharma’s revised bid, saying it “substantially undervalues” the company. Business • 23 May 13
Elan's board rejects Royalty Pharma's latest bid Elan’s board has unanimously rejected Royalty Pharma’s revised bid, saying it “substantially undervalues” the company. Business • 23 May 13
Royalty Pharma raises Elan bid Royalty Pharma last night raised its hostile bid for Elan to $12.50 per share. Business • 21 May 13
Royalty Pharma raises Elan bid Royalty Pharma last night raised its hostile bid for Elan to $12.50 per share. Business • 21 May 13
Royalty Pharma increases offer for Elan Royalty Pharma has revised its bid for Irish pharmaceutical company Elan, with an all-cash offer of $12.50 per share compared to the $11.25 offered previously. Business • 20 May 13
Royalty Pharma increases offer for Elan Royalty Pharma has revised its bid for Irish pharmaceutical company Elan, with an all-cash offer of $12.50 per share compared to the $11.25 offered previously. Business • 20 May 13
Elan in $1 billion royalty deal with Theravance Elan has today announced a new royalty participation agreement with Theravance. Business • 13 May 13
Elan in $1 billion royalty deal with Theravance Elan has today announced a new royalty participation agreement with Theravance. Business • 13 May 13
Royalty Pharma submits Elan offer Royalty Pharma today formally submitted its $11.25 per share bid for Elan to the company's shareholders. Business • 02 May 13
Royalty Pharma submits Elan offer Royalty Pharma today formally submitted its $11.25 per share bid for Elan to the company's shareholders. Business • 02 May 13
Elan says it has $2 billion in cash for deals Elan has reported a net loss from continuing operations of €72.8m for the three months to the end of March. Business • 24 Apr 13
Elan says it has $2 billion in cash for deals Elan has reported a net loss from continuing operations of €72.8m for the three months to the end of March. Business • 24 Apr 13
